PubMed=26095605; DOI=10.1016/j.stemcr.2015.05.010
Cusulin C., Chesnelong C., Bose P., Bilenky M., Kopciuk K., Chan J.A.W., Cairncross J.G., Jones S.J.M., Marra M.A., Luchman H.A., Weiss S.
Precursor states of brain tumor initiating cell lines are predictive of survival in xenografts and associated with glioblastoma subtypes.
Stem Cell Reports 5:1-9(2015)

PubMed=26245525; DOI=10.1093/neuonc/nov143
Davis B., Shen Y.-Q., Poon C.C., Luchman H.A., Stechishin O.D.M., Pontifex C.S., Wu W., Kelly J.J.P., Blough M.D.
Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.
Neuro-oncol. 18:350-360(2016)

PubMed=30153289; DOI=10.1371/journal.pone.0202860
Yuan A.L., Ricks C.B., Bohm A.K., Lun X.-Q., Maxwell L., Safdar S., Bukhari S., Gerber A., Sayeed W., Bering E.A., Pedersen H., Chan J.A.W., Shen Y.-Q., Marra M., Kaplan D.R., Mason W., Goodman L.D., Ezhilarasan R., Kaufmann A.B., Cabral M., Robbins S.M., Senger D.L., Cahill D.P., Sulman E.P., Cairncross J.G., Blough M.D.
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
PLoS ONE 13:E0202860-E0202860(2018)